Difelikefalin (Kapruvia®). HTA ID: 23001

Assessment Status NCPE Assessment Process Complete
HTA ID 23001
Drug Difelikefalin
Brand Kapruvia®
Indication For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.
Assessment Process
Rapid review commissioned 09/01/2023
Rapid review completed 02/02/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of difelikefalin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/03/2023
Pre-submission consultation with Applicant 16/05/2023
Full submission received from Applicant 12/09/2023
Preliminary review sent to Applicant 24/11/2023
NCPE assessment re-commenced 21/12/2023
Factual accuracy sent to Applicant 22/01/2024
NCPE assessment re-commenced 29/01/2024
NCPE assessment completed 06/02/2024
NCPE assessment outcome The NCPE recommends that difelikefalin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.